Brivanib Alaninate

丙氨酸布立尼布

Report date: 2025/02/07 16:52:25
NME

Base Information

Drug NameBrivanib Alaninate
Drug Alias Name丙氨布利伐尼Alaninati brivanibumBrivanibZL-2301BMS-582664 +[6] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists
TargetsFibroblast growth factor receptor 1Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursPulmonary Disease, Chronic ObstructiveAsthma +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhuhai Yuedong Network Technology Co Ltd
Inactive CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdZai Lab (Shanghai) Co Ltd +[7] 
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsSolid tumoursNeoplasm MetastasisUterine Cervical Neoplasms +[16] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG